Scholarlink

Introduction <p>Diabetes is a known risk factor for surgical-site infection (SSI) following total joint arthroplasty (TJA), but the impact of antidiabetic medications on outcomes remains unclear. This study investigated the association between medication regimen, clinical outcomes, and glycemic control in patients with Type 2 diabetes (T2DM).</p> Methods <p>We retrospectively reviewed T2DM patients undergoing primary, elective TJA from 2011 to 2022. Patients were stratified by their antidiabetic medication regimen taken for at least one month in the year preoperatively: (1) one medication, (2) 2 + medications, and (3) insulin-containing regimen. Cohorts were matched by preoperative hemoglobin A1c (HbA1c), age, body-mass index (BMI), sex, and ASA class. Demographics, outcomes, and glycemic markers were compared.</p> Results <p>Of 2767 TJAs, 55.4%, 30.1%, and 14.5% fell into Cohorts 1, 2, and 3, respectively. After matching, each cohort included 273 procedures. Insulin-treated patients had greater blood glucose variability during hospitalization (153.7 vs. 114.8 [1] &amp; 119.0 [2]; <i>P</i> &lt; 0.001). Long-term outcomes, revision incidence, and SSIs did not differ significantly across cohorts. In regression of the pre-match population, insulin-containing regimens (OR: 2.8; <i>P</i> = 0.015), higher BMI (OR: 1.1; <i>P</i> = 0.002), and elevated preoperative HbA1c (OR: 1.3; <i>P</i> = 0.049) predicted SSI following THA. No significant predictors of SSI after TKA were found, and medication regimen was not associated with revision risk.</p> Conclusion <p>Patients with T2DM on insulin-containing regimens exhibited worse perioperative glycemic control and increased SSI incidence after THA, although medication regimen did not affect outcomes after TKA. Our findings are the first to suggest that insulin requirements in patients with T2DM, independent of glycemic control measured with preoperative HbA1c, may influence infection risk following THA and complicate perioperative glycemic control after TJA. We emphasize the importance of perioperative optimization and proactive management of these higher-risk patients, regardless of their preoperative HbA1c.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-diabetic medications’ effect on outcomes and glycemic markers following TJA in patients with type 2 diabetes

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Garrett Ruff,
  • Sophia S Antonioli,
  • John Cordero,
  • Anna Cohen-Rosenblum,
  • Ran Schwarzkopf,
  • Joshua C Rozell

摘要

Introduction

Diabetes is a known risk factor for surgical-site infection (SSI) following total joint arthroplasty (TJA), but the impact of antidiabetic medications on outcomes remains unclear. This study investigated the association between medication regimen, clinical outcomes, and glycemic control in patients with Type 2 diabetes (T2DM).

Methods

We retrospectively reviewed T2DM patients undergoing primary, elective TJA from 2011 to 2022. Patients were stratified by their antidiabetic medication regimen taken for at least one month in the year preoperatively: (1) one medication, (2) 2 + medications, and (3) insulin-containing regimen. Cohorts were matched by preoperative hemoglobin A1c (HbA1c), age, body-mass index (BMI), sex, and ASA class. Demographics, outcomes, and glycemic markers were compared.

Results

Of 2767 TJAs, 55.4%, 30.1%, and 14.5% fell into Cohorts 1, 2, and 3, respectively. After matching, each cohort included 273 procedures. Insulin-treated patients had greater blood glucose variability during hospitalization (153.7 vs. 114.8 [1] & 119.0 [2]; P < 0.001). Long-term outcomes, revision incidence, and SSIs did not differ significantly across cohorts. In regression of the pre-match population, insulin-containing regimens (OR: 2.8; P = 0.015), higher BMI (OR: 1.1; P = 0.002), and elevated preoperative HbA1c (OR: 1.3; P = 0.049) predicted SSI following THA. No significant predictors of SSI after TKA were found, and medication regimen was not associated with revision risk.

Conclusion

Patients with T2DM on insulin-containing regimens exhibited worse perioperative glycemic control and increased SSI incidence after THA, although medication regimen did not affect outcomes after TKA. Our findings are the first to suggest that insulin requirements in patients with T2DM, independent of glycemic control measured with preoperative HbA1c, may influence infection risk following THA and complicate perioperative glycemic control after TJA. We emphasize the importance of perioperative optimization and proactive management of these higher-risk patients, regardless of their preoperative HbA1c.